1. Longitudinal follow-up of metformin treatment in Fragile X Syndrome
- Author
-
Seng, Panhaneath, Montanaro, Federica Alice Maria, Biag, Hazel Maridith Barlahan, Salcedo-Arellano, Maria Jimena, Kim, Kyoungmi, Ponzini, Matthew Dominic, Tassone, Flora, Schneider, Andrea, Abbeduto, Leonard, Thurman, Angela John, Hessl, David, Bolduc, Francois V, Jacquemont, Sebastien, Lippé, Sarah, and Hagerman, Randi J
- Subjects
Biological Psychology ,Psychology ,Brain Disorders ,Intellectual and Developmental Disabilities (IDD) ,Mental Health ,Behavioral and Social Science ,Fragile X Syndrome ,Rare Diseases ,6.1 Pharmaceuticals ,metformin ,fragile X syndrome ,treatment ,IQ ,adaptive behavior ,longitudinal follow-up ,Cognitive Sciences ,Biomedical and clinical sciences - Abstract
IntroductionMetformin has been used as a targeted treatment to potentially improve cognition and slow the typical IQ decline that occurs during development among individuals with fragile X syndrome (FXS). In this follow-up study, we are following the trajectory of IQ and adaptive behavior changes over 1 to 3 years in individuals with FXS who are clinically treated with metformin in an open label trial.MethodIndividuals with FXS ages 6 to 25 years (mean 13.15 ± 5.50) and nonverbal IQ mean 57.69 (±15.46) were treated for 1-3 years (1.88 ± 0.63). They all had a baseline IQ test using the Leiter-III non-verbal cognitive assessment and the Vineland-III adaptive behavior assessment before the start of metformin. Repeat Leiter-III and Vineland-III were completed after at least 1 year of metformin (500-1,000 mg/dose given twice a day).ResultThere were no significant changes in non-verbal IQ or in the adaptive behavior measurements at FDR
- Published
- 2024